From their prognostic signature, they revealed that SPTBN1 could serve as an independent predictor of predicting OS of pancreatic ductal adenocarcinoma (PDAC) under clinical settings; they also found higher expression of SPTBN1 was associated with longer survival in patients with PDAC[50]. This evidence concerns the gene SPTBN1 and pancreatic ductal adenocarcinoma.